Outcomes of acute exacerbation of severe congestive heart failure: Quality of life, resource use, and survival

Archives of Internal Medicine

Volumn 158, Issue 10, 1998, Pages 1081-1089

  Jaagosild, Priit ^a   Dawson, Neal V ^a   Thomas, Charles ^a   Wenger, Neil S ^b   Tsevat, Joel ^b   Knaus, William A ^c   Califf, Robert M ^d   Goldman, Lee ^e   Vidaillet, Humberto ^f   Connors Jr , Alfred F ^c  

^a METROHEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL;

EID: 0032565604     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.10.1081     Document Type: Article

References (73)

1. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22(suppl A):6A-13A.
2. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301-306.
3. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med. 1990;150:769-773.
4. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994;344:493-498.
5. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol. 1994;74:674-680.
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 1993;342:821-828.
7. Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(suppl A):14A-19A.
8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1992;327:685-691.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
10. Eichhorn EJ, Tandon PK, DiBianco R, et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE study. J Am Coll Cardiol. 1993;21:634-640.
11. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
12. Pfeffer MA, Braunvald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:667-677.
13. Jaeger AA, Hlatky MA, Paul SM, Gortner SR. Functional capacity after cardiac surgery in elderly patients. J Am Coll Cardiol. 1994;24:104-108.
14. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the medical outcomes study. JAMA. 1989;262:907-913.
15. Rogers WJ, Johnstone DE, Yusuf S, et al. Quality of life among 5025 patients with left ventricular dysfunction randomized between placebo and enalapril: the studies of left ventricular dysfunction. J Am Coll Cardiol. 1994;23:393-400.
16. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
17. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? a trial of enoximone. Br Heart J. 1994;72:226-230.
18. Seneviratne B, Moore GA, West PD. Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomized double blind placebo controlled trial. Br Heart J. 1994;72:63-68.
19. Rector TS, Johnson G, Dunkman B, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus dinitrate on quality of life: V-HeFT II. Circulation. 1993;87(suppl VI):VI71-VI77.
20. Stevenson WG, Middlekauff HR, Stevenson LW, Saxon LA, Woo MA, Moser D. Significance of aborted cardiac arrest and sustained ventricular tachycardia in patients referred for treatment therapy of advanced heart failure. Am Heart J. 1992;124:123-130.
21. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19:842-850.
22. White M, Rouleau JL, Ruddy TD, DeMarco T, Moher D, Chatterjee K. Decreased coronary sinus oxygen content: a predictor of adverse prognosis in patients with severe congestive heart failure. J Am Coll Cardiol. 1991;18:1631-1637.
23. Keogh AM, Freund J, Baron DW, Hickie JB. Timing of cardiac transplantation in idiopathic dilated cardiomyopathy. Am J Cardiol. 1988;61:418-422.
24. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429-1435.
25. Kelly TL, Cremo R, Nielsen C, Shabetai R. Prediction of outcome in late-stage cardiomyopathy. Am Heart J. 1990;119:1111-1121.
26. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:831-836.
27. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol. 1990;65:903-908.
28. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation. 1991;84:40-48.
29. Anderson B, Waagstein F. Spectrum and outcome of congestive heart failure in a hospitalized population. Am Heart J. 1993;126:632-640.
30. Smith RF, Johnson G, Ziesche S, Bhat G, Blankenship K, Cohn JN. Functional capacity in heart failure: comparison of methods for assessment and their relation to other indexes of heart failure. Circulation. 1993;87(suppl VI):VI88-VI93.
31. Wegner NK, Mattson ME, Furberg CD, Elinson J. Assessment of quality of life in clinical trials of cardiovascular therapies. Am J Cardiol. 1984;54:908-913.
32. Guyatt GH. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol. 1993;22(supplA):165A-191A.
33. Burns RB, McCarthy EP, Moskowitz MA, et al. Outcomes for older men and women with congestive heart failure. J Am Geriatr Soc. 1997;45:276-280.
34. Murphy DJ, Cluff LE. SUPPORT: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments: study design. J Clin Epidemiol. 1990;43(suppl):1S-123S.
35. Hamel MB, Goldman L, Teno J, et al. Identification of comatose patients at high risk for death or severe disability: SUPPORT investigators: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. JAMA. 1995;273:1842-1848.
36. Covinsky KE, Goldman L, Cook EF, et al. The impact of serious illness on patients' families: SUPPORT investigators: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. JAMA. 1994;272:1839-1844.
37. Knaus WA, Harrell FE Jr, Lynn J, et al. The SUPPORT prognostic model: objective estimates of survival for seriously ill hospitalized adults: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Ann Intern Med. 1995;122:191-203.
38. Tsevat J, Cook EF, Green ML, et al. Health values of the seriously ill. Ann Intern Med. 1994;122:514-520.
39. Phillips RS, Wenger NS, Teno J, et al. Choices of seriously ill patients about cardiopulmonary resuscitation: correlates and outcomes. Am J Med. 1996;100:128-137.
40. Murphy DJ, Knaus WA, Lynn J. Study population in SUPPORT: patients (as defined by disease categories and mortality projections), surrogates, and physicians. J Clin Epidemiol. 1990;43(suppl):11S-28S.
41. Phillips RS, Knaus WA. Patient characteristics in SUPPORT: sociodemographics, admission diagnosis, co-morbidities and acute physiology score. J Clin Epidemiol. 1990;43(suppl):29S-31S.
42. Phillips RS, Goldman L, Bergner M. Patient characteristics in SUPPORT: activity status and cognitive function. J Clin Epidemiol. 1990;43(suppl):33S-36S.
43. Oye RK, Landefeld CS, Jayes RL. Outcomes in SUPPORT. J Clin Epidemiol. 1990;43(suppl):83S-87S.
44. Landefeld CS, Phillips RS, Bergner M. Patient characteristics in SUPPORT: functional status. J Clin Epidemiol. 1990;43(suppl):37S-39S.
45. Tsevat J, Dawson NV, Matchar DB. Assessing quality of life and preferences in the seriously ill using utility theory. J Clin Epidemiol. 1990;43(suppl):73S-77S.
46. Kreling B, Robinson DK, Bergner M. Data collecting strategies in SUPPORT. J Clin Epidemiol. 1990;43(suppl):5S-9S.
47. Phillips RS, Murphy DJ, Goldman L, Knaus WA. Patient characteristics in SUPPORT: disease specific clinical data. J Clin Epidemiol. 1990;43(suppl):41S-45S.
48. Knaus WA, Wagner DP, Draper EA, et al. APACHE III. Crit Care Med. 1989;17 (suppl 12):S176-S221.
49. Knaus WA, Wagner DP, Draper EA, et al. APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100:1619-1636,
50. Teasdale G, Murray G, Parker L, Jennett B. Adding up the Glasgow Coma Score. Acta Neurochir Suppl (Wien). 1979;28(1):13-16.
51. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64:651-654.
52. Nelson CL, Herndon JE, Mark DB, Pryor DB, Califf RM, Hlatky MA. Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. Am J Cardiol. 1991;61:973-975.
53. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981;19:787-805.
54. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe W. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
55. Katz S, Akpom CA. A measure of primary sociobiological function. Int J Health Serv. 1976;6:493-508.
56. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-629.
57. Stewart AL, Hays RD, Ware JE. The MOS Short-term General Health Survey: reliability and validity in a patient population. Med Care. 1988;26:724-735.
58. Revicki DA, Kaplan RM. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res. 1993;2:477-487.
59. Tsevat J, Goldman L, Lamas GA, et al. Functional status versus utilities in survivors of myocardial infarction. Med Care. 1991;29:1153-1159.
60. Cullen DJ, Civetta JM, Briggs BA, Ferrara LC. Therapeutic intervention scoring system: a method for quantitative comparison of patient care. Crit Care Med. 1974;2:57-60.
61. Keene AR, Cullen DJ. Therapeutic intervention scoring system: update 1983. Crit Care Med. 1983;11:1-3.
62. Teno JM, Hakim RB, Knaus WA, et al. Preferences for cardiopulmonary resuscitation: physician-patient agreement and hospital resource use: the SUPPORT Investigators. J Gen Intern Med. 1995;10:179-186.
63. Wu AW, Damiano AM, Lynn J, et al. Predicting future functional status for seriously ill hospitalized adults: the SUPPORT prognostic model. Ann Intern Med. 1995;122:342-350.
64. Fletcher A, McLoone P, Bulpitt C. Quality of life on angina therapy: a randomized controlled trial of transdermal glyceryl trinitrate against placebo. Lancet. 1988;2:4-7.
65. Miranda DR. Quality of life after cardiopulmonary resuscitation. Chest. 1994;106:524-530.
66. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-165.
67. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
68. Hlatky MA, Charles ED, Nobrega F. et al. Initial functional and economic status of patients with multivessel coronary artery disease randomized in the bypass angioplasty revascularization investigation (BARI). Am J Cardiol. 1995;75:34C-41C.
69. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation. 1992;85:942-949.
70. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living With Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J. 1992;124:1017-1027.
71. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living With Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71:1106-1107.
72. US Bureau of the Census. Statistical Abstract of the United States: 1994. 114th ed. Washington, DC: US Bureau of the Census; 1994.
73. Layde PM, Broste SK, Desbiens N, et al. Generalizability of clinical studies conducted at tertiary care medical centers: a population-based analysis. J Clin Epidemiol. 1996;49:835-841.